MARKET NEWS

Novavax Confirms Accelerated Approval Pathway Available for Licensure of NanoFlu
Atossa Genetics Preliminary Phase 2 Study Achieves Primary Endpoint
Wave Life Sciences Announces Initiation of Phase 2/3 Clinical Trial 
SunGen Pharma Announces Partnership With Athenex Pharmaceutical
Seelos Therapeutics Announces Acquisition of Exclusive Worldwide License of Gene Therapy Program
Esperion & Oberland Capital Announce $200-Million Agreement

  FEATURED EDITORIAL

  COMPANY PROFILE

Ligand-owned, Captisol was invented in 1990 by scientists at the University of Kansas Higuchi Biosciences Center for use in drug development and formulation. The Captisol technology is used to address the limitations of currently marketed drugs. Eleven FDA-approved, Captisol-enabled medications are marketed by: Pfizer, Bristol-Myers Squibb, and Baxter International. Captisol also has License and Supply Agreements (LSAs) in place with a number of pharmaceutical companies worldwide with Captisol-enabled product candidates. Routes of administration investigated include parenteral, oral, ophthalmic, nasal, topical, oral, and inhalation. Click here for more.

  EXCLUSIVE ONLINE CONTENT

2019 Respiratory Drug Development eBook - Increased Focus on Respiratory Drug & Device Development Makes Treatment More Personal

2019 Respiratory Drug Development eBook - Increased Focus on Respiratory Drug & Device Development Makes Treatment More Personal

This e-Book highlights some of the innovators and innovations in the respiratory sector, addresses the importance of end users in the device development process, and presents recent advancements in improving patient adherence.

Athenex Announces Strategic Global Initiatives 

Athenex Announces Strategic Global Initiatives 

Athenex, Inc. recently announced it has strategically expanded its presence in Europe and Latin America to grow its global……

Arcturus Therapeutics Receives Orphan Drug Designation

Arcturus Therapeutics Receives Orphan Drug Designation

Arcturus Therapeutics Holdings Inc. recently announced the US FDA has granted Orphan Drug Designation for the company’s lead product candidate………

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

July 31 – Excipients
August 7 – Controlled Release